Peter J. Weiden, MD

Renaissance School of Medicine at Stony Brook University, Stony Brook, New York

JCP
Aripiprazole Lauroxil Initiation Regimens
Original Research

August 12, 2024

In separate studies of the two initiation methods, the numbers of people who had side effects were similar, and most side effects were mild.
Roger W. Sommi, Stephen R. Saklad, Peter J. Weiden, et al
JCP
Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)
Original Research

image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ May 11, 2022

This post hoc analysis of phase 2 data evaluated rates and time course of response with the new combination oral agent KarXT (xanomeline−trospium) in the treatment of schizophrenia.
Peter J. Weiden, Alan Breier, Sarah Kavanagh, et al
JCP
Original Research

August 18, 2020

Long-acting injectable (LAI) antipsychotics improve adherence, reduce treatment gaps, and improve clinical outcomes. This report describes the long-term safety, tolerability, and symptom trajectory with the LAI antipsychotic aripiprazole lauroxil.
John Lauriello, Amy Claxton, Yangchun Du, et al
JCP
Original Research

May 19, 2020

Read a study examining the efficacy and tolerability of the long-acting injectable (LAI) aripiprazole lauroxil from inpatient into follow-up outpatient care.
Peter J. Weiden, Amy Claxton, Jelena Kunovac, et al
JCP
Original Research

September 19, 2017

Injectable antipsychotics can help address the problem of nonadherence, which can lead to relapse. This study looks at the efficacy of the injectable antipsychotic aripiprazole lauroxil in achieving and...
Joseph P. McEvoy, Robert Risinger, Serhiy Mykhnyak, et al
JCP
Original Research

August 23, 2017

Read the results on whether a longer half-life is associated with longer time to relapse after antipsychotic discontinuation, even among LAI formulations.
Peter J. Weiden, Edward Kim, Jason Bermak, et al
JCP
Original Research

August 23, 2017

What are the primary causes of poor patient outcomes in psychiatry, and what can be done to address these? A panel of 58 experts in psychiatry completed a survey...
Ainslie Hatch, John P. Docherty, Daniel Carpenter, et al
JCP
Commentary

May 25, 2016

Peter J. Weiden
JCP
Original Research

June 24, 2015

Peter J. Weiden, Rebecca S. Roma, Dawn I. Velligan, et al
JCP
Academic Highlights

October 23, 2013

John W. Newcomer, Peter J. Weiden, Robert W. Buchanan
JCP
Original Research

April 19, 2013

Noam Y. Kirson, Peter J. Weiden, Sander Yermakov, et al
JCP
Original Research

August 7, 2012

Peter J. Weiden, Nina R. Schooler, Jeremy C. Weedon, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe